Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany.

AIM Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). METHODS The primary outcome was direct and indirect costs in patients with ALL/DLBCL/FL who received HSCT between 2010 and 2014. Costs were evaluated two to four quarters before to eight quarters after HSCT. RESULTS Among 258 patients with HSCT, direct costs were €290,125/patient (pediatric ALL), €246,266/patient (adult ALL), €230,399/patient (DLBCL/FL allogeneic) and €107,457/patient (DLBCL/FL autologous). Indirect costs with HSCT were €52,939/patient (adult ALL), €20,285/patient (DLBCL/FL allogeneic) and €29,881/patient (DLBCL/FL autologous). CONCLUSION Direct and indirect costs associated with HSCT are substantial for patients with ALL, DLBCL and FL. Novel therapies that reduce HSCT use could reduce medical costs.

[1]  R. Maziarz,et al.  Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma , 2018, Leukemia & lymphoma.

[2]  M. Hamadani,et al.  Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. , 2017, Hematology/oncology and stem cell therapy.

[3]  T Terwilliger,et al.  Acute lymphoblastic leukemia: a comprehensive review and 2017 update , 2017, Blood Cancer Journal.

[4]  M. Provencio,et al.  Follicular lymphomas and their transformation: Past and current research , 2017, Expert review of hematology.

[5]  V. Havelange,et al.  Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium , 2017, Acta clinica Belgica.

[6]  H. Dombret,et al.  Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review , 2016, Journal of Medical Economics.

[7]  R. Maziarz,et al.  Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant. , 2016, International journal of hematologic oncology.

[8]  F. Andersohn,et al.  Characteristics and external validity of the German Health Risk Institute (HRI) Database , 2016, Pharmacoepidemiology and drug safety.

[9]  E. Swart,et al.  [STandardized Reporting Of Secondary data Analyses (STROSA)—a recommendation]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[10]  T. Arneson,et al.  Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation in the United States: A Study Using a Large National Private Claims Database , 2012, Bone Marrow Transplantation.

[11]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[12]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[13]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.